Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.66 |
| ▸ | GAA | P10253 | 7/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.66 |
| ▸ | MAPT | P10636 | 5/20 | 0.66 |
| ▸ | HPGD | P15428 | 5/20 | 0.66 |
| ▸ | GLA | P06280 | 2/20 | 0.66 |
| ▸ | CASP1 | P29466 | 1/20 | 0.66 |
| ▸ | CASP7 | P55210 | 1/20 | 0.66 |
| ▸ | ATM | Q13315 | 1/20 | 0.66 |
| ▸ | ABL1 | P00519 | 1/20 | 0.64 |
| ▸ | CFTR | P13569 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | THRB | P10828 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL267307 | 0.85 | KDM4E (0.62) | ALDH1A1KDM4EGAAHSD17B10MAPT | |
| SCHEMBL9929149 | 0.85 | NPC1 (0.63) | ALDH1A1KDM4EGAAHSD17B10MAPT | |
| Hydrochloric Acid SCHEMBL5100210 | 0.84 | ALDH1A1 (0.60) | ALDH1A1KDM4EGAAHSD17B10MAPT | |
| SCHEMBL312677 | 0.83 | ALDH1A1 (0.65) | ALDH1A1KDM4EGAAHSD17B10MAPT | |
| SCHEMBL148855 | 0.83 | ALDH1A1 (0.53) | ALDH1A1KDM4EGAAMAPTHPGD | |
| SCHEMBL29976235 | 0.83 | ALDH1A1 (0.65) | ALDH1A1KDM4EGAAHSD17B10MAPT | |
| SCHEMBL147211 | 0.83 | SMN1; SMN2 (0.54) | ALDH1A1KDM4EGAAMAPTHPGD | |
| SCHEMBL22749333 | 0.83 | ALDH1A1 (0.58) | ALDH1A1KDM4EGAAHSD17B10MAPT | |
| SCHEMBL7685381 | 0.83 | CFTR (0.65) | ALDH1A1KDM4EGAAHSD17B10MAPT | |
| SCHEMBL10362606 | 0.83 | ALDH1A1 (0.58) | ALDH1A1KDM4EGAAHSD17B10MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 283 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4288362-A | Monoazo pigments containing a quinazo linonylacetoacetanilide coupling component | BAYER AKTIENGESELLSCHAFT (DE) | 1981-09-08 | — | — | US | claimed |
| EP-4733299-A1 | SULFUR-CONTAINING FUSED RING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Shenzhen Braegen Pharmaceutical Co., Ltd. (CN) | 2026-04-29 | — | — | EP | disclosed |
| US-12606522-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | ORSOBIO, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20260085058-A1 | DEGRADERS OF SON OF SEVENLESS HOMOLOG 1 | YUAN YU (US) | 2026-03-26 | — | — | US | disclosed |
| US-12565511-B2 | SOS1 inhibitor containing phosphorus | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2026-03-03 | — | — | US | disclosed |
| US-20260022135-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | 1CBIO INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-12485169-B2 | Compounds | Grey Wolf Therapeutics Limited (GB) | 2025-12-02 | — | — | US | disclosed |
| US-20250243171-A1 | QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE | ARTHROSI THERAPEUTICS, INC. | 2025-07-31 | — | — | US | disclosed |
| US-12325720-B2 | Ectonucleotide pyrophosphatase-phosphodiesterase-1 (ENPP1) inhibitors and uses thereof | 1CBIO, INC. (US) | 2025-06-10 | — | — | US | disclosed |
| CN-115677601-B | Compound with anti-tumor activity and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2025-06-03 | — | — | CN | disclosed |
| EP-0093922-A2 | Benzoxazin-2-ones, their preparation and therapeutic agents containing these compounds | Dr. Karl Thomae GmbH (DE) | 1983-11-16 | — | — | EP | disclosed |
| US-4377581-A | ANTIHYPERTENSIVE AGENTS | PFIZER INC. (US) | 1983-03-22 | — | — | US | disclosed |
| US-4351940-A | Chloro- and alkoxy-substituted-2-chloro-4-aminodquinazolines | PFIZER INC. (US) | 1982-09-28 | — | — | US | disclosed |
| US-4288362-A | Monoazo pigments containing a quinazo linonylacetoacetanilide coupling component | BAYER AKTIENGESELLSCHAFT (DE) | 1981-09-08 | — | — | US | disclosed |
| US-4287341-A | USEFUL AS ANTIHYPERTENSIVE AGENTS | PFIZER INC. (US) | 1981-09-01 | — | — | US | disclosed |
| EP-0028473-A1 | Chloro- and alkoxy-substituted-2,4-diaminoquinazolines and pharmaceutical compositions containing them | PFIZER INC. (US) | 1981-05-13 | — | — | EP | disclosed |
| US-4260540-A | SPIN DYEING POLYACRYLONITRILE | BAYER AKTIENGESELLSCHAFT (DE) | 1981-04-07 | — | — | US | disclosed |
| US-4246401-A | Axomethine pigments | BAYER AKTIENGESELLSCHAFT (DE) | 1981-01-20 | — | — | US | disclosed |
| US-4225489-A | Heterocyclic azo dyes and pigments containing 4-quinazolinone moieties | BAYER AKTIENGESELLSCHAFT (DE) | 1980-09-30 | — | — | US | disclosed |
| US-4014863-A | LACQUERS, PRINTING INKS, PAINTS | BAYER AKTIENGESELLSCHAFT (DT) | 1977-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022135-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE-1 (ENPP1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, NCEH1 | ALDH1A1 2453/4885KDM4E 4523/4885GAA 1454/4885 |
| US-20250243171-A1 | QUINAZOLINE COMPOUNDS FOR TREATMENT OF DISEASE | EGFR, ABL1, ERBB2 | ALDH1A1 2795/4885KDM4E 3572/4885GAA 1111/4885 |
| US-12565511-B2 | SOS1 inhibitor containing phosphorus | SOST, SOS1, SOS2 | ALDH1A1 4510/4885KDM4E 4495/4885GAA 3203/4885 |
| US-12325720-B2 | Ectonucleotide pyrophosphatase-phosphodiesterase-1 (ENPP1) inhibitors and uses thereof | ENPP1, ENPP3, ENPP2 | ALDH1A1 754/4885KDM4E 3129/4885GAA 189/4885 |
| US-12606522-B2 | Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives | NR3C2, NR5A1, SRD5A2 | ALDH1A1 1507/4885KDM4E 3921/4885GAA 2559/4885 |
| US-12485169-B2 | Compounds | SLC10A1, VHL, CFTR | ALDH1A1 276/4885KDM4E 4372/4885GAA 96/4885 |
| US-20260085058-A1 | DEGRADERS OF SON OF SEVENLESS HOMOLOG 1 | SOS1, KRAS, SOS2 | ALDH1A1 1136/4885KDM4E 924/4885GAA 4426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.